Because of their hydrophobicity, lipids are found in the extracellular spaces of the human body primarily in the form of lipoprotein complexes. Chylomicrons form in the small intestine and transport dietary lipids to other tissues in the body. Very low density lipoproteins (VLDL) form in the liver and transport triacylglycerol synthesized there to other tissues of the body. As they circulate, VLDL are acted on by lipoprotein lipases on the endothelial surfaces of blood vessels, liberating fatty acids and glycerol to be taken up by tissues and converting the VLDL first to intermediate density lipoproteins (IDL) and then to low density lipoproteins (LDL). IDL and LDL are cleared from the circulation via a specific cell surface receptor, found in the body primarily on the surfaces of liver cells. High density lipoprotein (HDL) particles, initially formed primarily by the liver, shuttle several kinds of lipids between tissues and other lipoproteins. Notably, they are responsible for the so-called reverse transport of cholesterol from peripheral tissues to LDL for return to the liver.
Three aspects of lipoprotein function are currently annotated in Reactome: chylomicron-mediated lipid transport, LDL endocytosis and degradation, and HDL-mediated lipid transport, each divided into assembly, remodeling, and clearance subpathways.
View original pathway at Reactome.</div>
Adimoolam S, Jin L, Grabbe E, Shieh JJ, Jonas A.; ''Structural and functional properties of two mutants of lecithin-cholesterol acyltransferase (T123I and N228K).''; PubMedEurope PMCScholia
Infante RE, Wang ML, Radhakrishnan A, Kwon HJ, Brown MS, Goldstein JL.; ''NPC2 facilitates bidirectional transfer of cholesterol between NPC1 and lipid bilayers, a step in cholesterol egress from lysosomes.''; PubMedEurope PMCScholia
Roubtsova A, Munkonda MN, Awan Z, Marcinkiewicz J, Chamberland A, Lazure C, Cianflone K, Seidah NG, Prat A.; ''Circulating proprotein convertase subtilisin/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue.''; PubMedEurope PMCScholia
He G, Gupta S, Yi M, Michaely P, Hobbs HH, Cohen JC.; ''ARH is a modular adaptor protein that interacts with the LDL receptor, clathrin, and AP-2.''; PubMedEurope PMCScholia
Dixon JL, Furukawa S, Ginsberg HN.; ''Oleate stimulates secretion of apolipoprotein B-containing lipoproteins from Hep G2 cells by inhibiting early intracellular degradation of apolipoprotein B.''; PubMedEurope PMCScholia
Shachter NS.; ''Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism.''; PubMedEurope PMCScholia
Xu S, Cheng J, Li NH, Chen YN, Cai MY, Tang SS, Huang H, Zhang B, Cen JM, Yang XL, Chen C, Liu X, Xiong XD.; ''The association of APOC4 polymorphisms with premature coronary artery disease in a Chinese Han population.''; PubMedEurope PMCScholia
Atzel A, Wetterau JR.; ''Identification of two classes of lipid molecule binding sites on the microsomal triglyceride transfer protein.''; PubMedEurope PMCScholia
Siezen RJ, Creemers JW, Van de Ven WJ.; ''Homology modelling of the catalytic domain of human furin. A model for the eukaryotic subtilisin-like proprotein convertases.''; PubMedEurope PMCScholia
Kontush A, Chapman MJ.; ''Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis.''; PubMedEurope PMCScholia
Zelcer N, Hong C, Boyadjian R, Tontonoz P.; ''LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor.''; PubMedEurope PMCScholia
Van Driel IR, Brown MS, Goldstein JL.; ''Stoichiometric binding of low density lipoprotein (LDL) and monoclonal antibodies to LDL receptors in a solid phase assay.''; PubMedEurope PMCScholia
Zhang Y, Ge G, Greenspan DS.; ''Inhibition of bone morphogenetic protein 1 by native and altered forms of alpha2-macroglobulin.''; PubMedEurope PMCScholia
Lookene A, Savonen R, Olivecrona G.; ''Interaction of lipoproteins with heparan sulfate proteoglycans and with lipoprotein lipase. Studies by surface plasmon resonance technique.''; PubMedEurope PMCScholia
Lee JH, Giannikopoulos P, Duncan SA, Wang J, Johansen CT, Brown JD, Plutzky J, Hegele RA, Glimcher LH, Lee AH.; ''The transcription factor cyclic AMP-responsive element-binding protein H regulates triglyceride metabolism.''; PubMedEurope PMCScholia
Lin S, Cheng D, Liu MS, Chen J, Chang TY.; ''Human acyl-CoA:cholesterol acyltransferase-1 in the endoplasmic reticulum contains seven transmembrane domains.''; PubMedEurope PMCScholia
Dewey FE, Gusarova V, O'Dushlaine C, Gottesman O, Trejos J, Hunt C, Van Hout CV, Habegger L, Buckler D, Lai KM, Leader JB, Murray MF, Ritchie MD, Kirchner HL, Ledbetter DH, Penn J, Lopez A, Borecki IB, Overton JD, Reid JG, Carey DJ, Murphy AJ, Yancopoulos GD, Baras A, Gromada J, Shuldiner AR.; ''Inactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease.''; PubMedEurope PMCScholia
Chang CC, Huh HY, Cadigan KM, Chang TY.; ''Molecular cloning and functional expression of human acyl-coenzyme A:cholesterol acyltransferase cDNA in mutant Chinese hamster ovary cells.''; PubMedEurope PMCScholia
Ameis D, Merkel M, Eckerskorn C, Greten H.; ''Purification, characterization and molecular cloning of human hepatic lysosomal acid lipase.''; PubMedEurope PMCScholia
Dijk W, Kersten S.; ''Regulation of lipoprotein lipase by Angptl4.''; PubMedEurope PMCScholia
Brown WV, Baginsky ML.; ''Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein.''; PubMedEurope PMCScholia
Swenson TL, Brocia RW, Tall AR.; ''Plasma cholesteryl ester transfer protein has binding sites for neutral lipids and phospholipids.''; PubMedEurope PMCScholia
Okazaki H, Igarashi M, Nishi M, Sekiya M, Tajima M, Takase S, Takanashi M, Ohta K, Tamura Y, Okazaki S, Yahagi N, Ohashi K, Amemiya-Kudo M, Nakagawa Y, Nagai R, Kadowaki T, Osuga J, Ishibashi S.; ''Identification of neutral cholesterol ester hydrolase, a key enzyme removing cholesterol from macrophages.''; PubMedEurope PMCScholia
Haraguchi G, Kobayashi Y, Brown ML, Tanaka A, Isobe M, Gianturco SH, Bradley WA.; ''PPAR(alpha) and PPAR(gamma) activators suppress the monocyte-macrophage apoB-48 receptor.''; PubMedEurope PMCScholia
Anderson RA, Byrum RS, Coates PM, Sando GN.; ''Mutations at the lysosomal acid cholesteryl ester hydrolase gene locus in Wolman disease.''; PubMedEurope PMCScholia
Rigotti A, Miettinen HE, Krieger M.; ''The role of the high-density lipoprotein receptor SR-BI in the lipid metabolism of endocrine and other tissues.''; PubMedEurope PMCScholia
Wang Y, Huang Y, Hobbs HH, Cohen JC.; ''Molecular characterization of proprotein convertase subtilisin/kexin type 9-mediated degradation of the LDLR.''; PubMedEurope PMCScholia
Chau P, Fielding PE, Fielding CJ.; ''Bone morphogenetic protein-1 (BMP-1) cleaves human proapolipoprotein A1 and regulates its activation for lipid binding.''; PubMedEurope PMCScholia
Sukonina V, Lookene A, Olivecrona T, Olivecrona G.; ''Angiopoietin-like protein 4 converts lipoprotein lipase to inactive monomers and modulates lipase activity in adipose tissue.''; PubMedEurope PMCScholia
Zhang L, Reue K, Fong LG, Young SG, Tontonoz P.; ''Feedback regulation of cholesterol uptake by the LXR-IDOL-LDLR axis.''; PubMedEurope PMCScholia
Hansen JB, Fernández JA, Notø AT, Deguchi H, Björkegren J, Mathiesen EB.; ''The apolipoprotein C-I content of very-low-density lipoproteins is associated with fasting triglycerides, postprandial lipemia, and carotid atherosclerosis.''; PubMedEurope PMCScholia
Adeyo O, Goulbourne CN, Bensadoun A, Beigneux AP, Fong LG, Young SG.; ''Glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 and the intravascular processing of triglyceride-rich lipoproteins.''; PubMedEurope PMCScholia
Kawakami A, Tani M, Chiba T, Yui K, Shinozaki S, Nakajima K, Tanaka A, Shimokado K, Yoshida M.; ''Pitavastatin inhibits remnant lipoprotein-induced macrophage foam cell formation through ApoB48 receptor-dependent mechanism.''; PubMedEurope PMCScholia
Liu J, Afroza H, Rader DJ, Jin W.; ''Angiopoietin-like protein 3 inhibits lipoprotein lipase activity through enhancing its cleavage by proprotein convertases.''; PubMedEurope PMCScholia
Bassi DE, Mahloogi H, Klein-Szanto AJ.; ''The proprotein convertases furin and PACE4 play a significant role in tumor progression.''; PubMedEurope PMCScholia
Gordon DA, Wetterau JR, Gregg RE.; ''Microsomal triglyceride transfer protein: a protein complex required for the assembly of lipoprotein particles.''; PubMedEurope PMCScholia
Daugherty A, Rateri DL, Lu H.; ''As macrophages indulge, atherosclerotic lesions bulge.''; PubMedEurope PMCScholia
Myocardial Infarction Genetics and CARDIoGRAM Exome Consortia Investigators, Stitziel NO, Stirrups KE, Masca NG, Erdmann J, Ferrario PG, König IR, Weeke PE, Webb TR, Auer PL, Schick UM, Lu Y, Zhang H, Dube MP, Goel A, Farrall M, Peloso GM, Won HH, Do R, van Iperen E, Kanoni S, Kruppa J, Mahajan A, Scott RA, Willenberg C, Braund PS, van Capelleveen JC, Doney AS, Donnelly LA, Asselta R, Merlini PA, Duga S, Marziliano N, Denny JC, Shaffer CM, El-Mokhtari NE, Franke A, Gottesman O, Heilmann S, Hengstenberg C, Hoffman P, Holmen OL, Hveem K, Jansson JH, Jöckel KH, Kessler T, Kriebel J, Laugwitz KL, Marouli E, Martinelli N, McCarthy MI, Van Zuydam NR, Meisinger C, Esko T, Mihailov E, Escher SA, Alver M, Moebus S, Morris AD, Müller-Nurasyid M, Nikpay M, Olivieri O, Lemieux Perreault LP, AlQarawi A, Robertson NR, Akinsanya KO, Reilly DF, Vogt TF, Yin W, Asselbergs FW, Kooperberg C, Jackson RD, Stahl E, Strauch K, Varga TV, Waldenberger M, Zeng L, Kraja AT, Liu C, Ehret GB, Newton-Cheh C, Chasman DI, Chowdhury R, Ferrario M, Ford I, Jukema JW, Kee F, Kuulasmaa K, Nordestgaard BG, Perola M, Saleheen D, Sattar N, Surendran P, Tregouet D, Young R, Howson JM, Butterworth AS, Danesh J, Ardissino D, Bottinger EP, Erbel R, Franks PW, Girelli D, Hall AS, Hovingh GK, Kastrati A, Lieb W, Meitinger T, Kraus WE, Shah SH, McPherson R, Orho-Melander M, Melander O, Metspalu A, Palmer CN, Peters A, Rader D, Reilly MP, Loos RJ, Reiner AP, Roden DM, Tardif JC, Thompson JR, Wareham NJ, Watkins H, Willer CJ, Kathiresan S, Deloukas P, Samani NJ, Schunkert H.; ''Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease.''; PubMedEurope PMCScholia
Lagor WR, Brown RJ, Toh SA, Millar JS, Fuki IV, de la Llera-Moya M, Yuen T, Rothblat G, Billheimer JT, Rader DJ.; ''Overexpression of apolipoprotein F reduces HDL cholesterol levels in vivo.''; PubMedEurope PMCScholia
Go GW, Mani A.; ''Low-density lipoprotein receptor (LDLR) family orchestrates cholesterol homeostasis.''; PubMedEurope PMCScholia
Gin P, Beigneux AP, Davies B, Young MF, Ryan RO, Bensadoun A, Fong LG, Young SG.; ''Normal binding of lipoprotein lipase, chylomicrons, and apo-AV to GPIHBP1 containing a G56R amino acid substitution.''; PubMedEurope PMCScholia
Anderson RA, Sando GN.; ''Cloning and expression of cDNA encoding human lysosomal acid lipase/cholesteryl ester hydrolase. Similarities to gastric and lingual lipases.''; PubMedEurope PMCScholia
Olofsson SO, Stillemark-Billton P, Asp L.; ''Intracellular assembly of VLDL: two major steps in separate cell compartments.''; PubMedEurope PMCScholia
Clark RW, Ruggeri RB, Cunningham D, Bamberger MJ.; ''Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action.''; PubMedEurope PMCScholia
Ji ZS, Fazio S, Lee YL, Mahley RW.; ''Secretion-capture role for apolipoprotein E in remnant lipoprotein metabolism involving cell surface heparan sulfate proteoglycans.''; PubMedEurope PMCScholia
Brown ML, Ramprasad MP, Umeda PK, Tanaka A, Kobayashi Y, Watanabe T, Shimoyamada H, Kuo WL, Li R, Song R, Bradley WA, Gianturco SH.; ''A macrophage receptor for apolipoprotein B48: cloning, expression, and atherosclerosis.''; PubMedEurope PMCScholia
Babilonia-Rosa MA, Neher SB.; ''Purification, cellular levels, and functional domains of lipase maturation factor 1.''; PubMedEurope PMCScholia
Liou HL, Dixit SS, Xu S, Tint GS, Stock AM, Lobel P.; ''NPC2, the protein deficient in Niemann-Pick C2 disease, consists of multiple glycoforms that bind a variety of sterols.''; PubMedEurope PMCScholia
Jin W, Fuki IV, Seidah NG, Benjannet S, Glick JM, Rader DJ.; ''Proprotein convertases [corrected] are responsible for proteolysis and inactivation of endothelial lipase.''; PubMedEurope PMCScholia
Kwon HJ, Abi-Mosleh L, Wang ML, Deisenhofer J, Goldstein JL, Brown MS, Infante RE.; ''Structure of N-terminal domain of NPC1 reveals distinct subdomains for binding and transfer of cholesterol.''; PubMedEurope PMCScholia
Griffon N, Jin W, Petty TJ, Millar J, Badellino KO, Saven JG, Marchadier DH, Kempner ES, Billheimer J, Glick JM, Rader DJ.; ''Identification of the active form of endothelial lipase, a homodimer in a head-to-tail conformation.''; PubMedEurope PMCScholia
Hussain MM, Shi J, Dreizen P.; ''Microsomal triglyceride transfer protein and its role in apoB-lipoprotein assembly.''; PubMedEurope PMCScholia
Lagor WR, Fields DW, Khetarpal SA, Kumaravel A, Lin W, Weintraub N, Wu K, Hamm-Alvarez SF, Drazul-Schrader D, de la Llera-Moya M, Rothblat GH, Rader DJ.; ''The effects of apolipoprotein F deficiency on high density lipoprotein cholesterol metabolism in mice.''; PubMedEurope PMCScholia
Morton RE, Zilversmit DB.; ''Inter-relationship of lipids transferred by the lipid-transfer protein isolated from human lipoprotein-deficient plasma.''; PubMedEurope PMCScholia
Beigneux AP, Franssen R, Bensadoun A, Gin P, Melford K, Peter J, Walzem RL, Weinstein MM, Davies BS, Kuivenhoven JA, Kastelein JJ, Fong LG, Dallinga-Thie GM, Young SG.; ''Chylomicronemia with a mutant GPIHBP1 (Q115P) that cannot bind lipoprotein lipase.''; PubMedEurope PMCScholia
Kotite L, Zhang LH, Yu Z, Burlingame AL, Havel RJ.; ''Human apoC-IV: isolation, characterization, and immunochemical quantification in plasma and plasma lipoproteins.''; PubMedEurope PMCScholia
Peterson J, Fujimoto WY, Brunzell JD.; ''Human lipoprotein lipase: relationship of activity, heparin affinity, and conformation as studied with monoclonal antibodies.''; PubMedEurope PMCScholia
Zhao B, Bie J, Wang J, Marqueen SA, Ghosh S.; ''Identification of a novel intracellular cholesteryl ester hydrolase (carboxylesterase 3) in human macrophages: compensatory increase in its expression after carboxylesterase 1 silencing.''; PubMedEurope PMCScholia
Singaraja RR, Kang MH, Vaid K, Sanders SS, Vilas GL, Arstikaitis P, Coutinho J, Drisdel RC, El-Husseini Ael D, Green WN, Berthiaume L, Hayden MR.; ''Palmitoylation of ATP-binding cassette transporter A1 is essential for its trafficking and function.''; PubMedEurope PMCScholia
Fielding CJ, Shore VG, Fielding PE.; ''A protein cofactor of lecithin:cholesterol acyltransferase.''; PubMedEurope PMCScholia
Bradley WA, Brown ML, Ramprasad MP, Li R, Song R, Gianturco SH.; ''Antipeptide antibodies reveal interrelationships of MBP 200 and MBP 235: unique apoB-specific receptors for triglyceride-rich lipoproteins on human monocyte-macrophages.''; PubMedEurope PMCScholia
Ren G, Kim JY, Smas CM.; ''Identification of RIFL, a novel adipocyte-enriched insulin target gene with a role in lipid metabolism.''; PubMedEurope PMCScholia
Jones B, Jones EL, Bonney SA, Patel HN, Mensenkamp AR, Eichenbaum-Voline S, Rudling M, Myrdal U, Annesi G, Naik S, Meadows N, Quattrone A, Islam SA, Naoumova RP, Angelin B, Infante R, Levy E, Roy CC, Freemont PS, Scott J, Shoulders CC.; ''Mutations in a Sar1 GTPase of COPII vesicles are associated with lipid absorption disorders.''; PubMedEurope PMCScholia
Michaely P, Li WP, Anderson RG, Cohen JC, Hobbs HH.; ''The modular adaptor protein ARH is required for low density lipoprotein (LDL) binding and internalization but not for LDL receptor clustering in coated pits.''; PubMedEurope PMCScholia
Li Y, Teng C.; ''Angiopoietin-like proteins 3, 4 and 8: regulating lipid metabolism and providing new hope for metabolic syndrome.''; PubMedEurope PMCScholia
Wu X, Zhou M, Huang LS, Wetterau J, Ginsberg HN.; ''Demonstration of a physical interaction between microsomal triglyceride transfer protein and apolipoprotein B during the assembly of ApoB-containing lipoproteins.''; PubMedEurope PMCScholia
Chin KT, Zhou HJ, Wong CM, Lee JM, Chan CP, Qiang BQ, Yuan JG, Ng IO, Jin DY.; ''The liver-enriched transcription factor CREB-H is a growth suppressor protein underexpressed in hepatocellular carcinoma.''; PubMedEurope PMCScholia
Denis M, Haidar B, Marcil M, Bouvier M, Krimbou L, Genest J.; ''Characterization of oligomeric human ATP binding cassette transporter A1. Potential implications for determining the structure of nascent high density lipoprotein particles.''; PubMedEurope PMCScholia
Zhu M, Zhao X, Chen J, Xu J, Hu G, Guo D, Li Q, Zhang X, Chang CC, Song B, Xiong Y, Chang T, Li B.; ''ACAT1 regulates the dynamics of free cholesterols in plasma membrane which leads to the APP-α-processing alteration.''; PubMedEurope PMCScholia
Marschner K, Kollmann K, Schweizer M, Braulke T, Pohl S.; ''A key enzyme in the biogenesis of lysosomes is a protease that regulates cholesterol metabolism.''; PubMedEurope PMCScholia
Murao K, Terpstra V, Green SR, Kondratenko N, Steinberg D, Quehenberger O.; ''Characterization of CLA-1, a human homologue of rodent scavenger receptor BI, as a receptor for high density lipoprotein and apoptotic thymocytes.''; PubMedEurope PMCScholia
Paule S, Aljofan M, Simon C, Rombauts LJ, Nie G.; ''Cleavage of endometrial α-integrins into their functional forms is mediated by proprotein convertase 5/6.''; PubMedEurope PMCScholia
Yen FT, Roitel O, Bonnard L, Notet V, Pratte D, Stenger C, Magueur E, Bihain BE.; ''Lipolysis stimulated lipoprotein receptor: a novel molecular link between hyperlipidemia, weight gain, and atherosclerosis in mice.''; PubMedEurope PMCScholia
Jackson RL, Tajima S, Yamamura T, Yokoyama S, Yamamoto A.; ''Comparison of apolipoprotein C-II-deficient triacylglycerol-rich lipoproteins and trioleoylglycerol/phosphatidylcholine-stabilized particles as substrates for lipoprotein lipase.''; PubMedEurope PMCScholia
Sakai K, Igarashi M, Yamamuro D, Ohshiro T, Nagashima S, Takahashi M, Enkhtuvshin B, Sekiya M, Okazaki H, Osuga J, Ishibashi S.; ''Critical role of neutral cholesteryl ester hydrolase 1 in cholesteryl ester hydrolysis in murine macrophages.''; PubMedEurope PMCScholia
Havel RJ, Kane JP, Kashyap ML.; ''Interchange of apolipoproteins between chylomicrons and high density lipoproteins during alimentary lipemia in man.''; PubMedEurope PMCScholia
See RH, Caday-Malcolm RA, Singaraja RR, Zhou S, Silverston A, Huber MT, Moran J, James ER, Janoo R, Savill JM, Rigot V, Zhang LH, Wang M, Chimini G, Wellington CL, Tafuri SR, Hayden MR.; ''Protein kinase A site-specific phosphorylation regulates ATP-binding cassette A1 (ABCA1)-mediated phospholipid efflux.''; PubMedEurope PMCScholia
Hill JS, Davis RC, Yang D, Schotz MC, Wong H.; ''Hepatic lipase: high-level expression and subunit structure determination.''; PubMedEurope PMCScholia
Beigneux AP, Fong LG, Bensadoun A, Davies BS, Oberer M, GÃ¥rdsvoll H, Ploug M, Young SG.; ''GPIHBP1 missense mutations often cause multimerization of GPIHBP1 and thereby prevent lipoprotein lipase binding.''; PubMedEurope PMCScholia
Hong C, Duit S, Jalonen P, Out R, Scheer L, Sorrentino V, Boyadjian R, Rodenburg KW, Foley E, Korhonen L, Lindholm D, Nimpf J, van Berkel TJ, Tontonoz P, Zelcer N.; ''The E3 ubiquitin ligase IDOL induces the degradation of the low density lipoprotein receptor family members VLDLR and ApoER2.''; PubMedEurope PMCScholia
Sorrentino V, Zelcer N.; ''Post-transcriptional regulation of lipoprotein receptors by the E3-ubiquitin ligase inducible degrader of the low-density lipoprotein receptor.''; PubMedEurope PMCScholia
Switzer S, Eder HA.; ''Transport of lysolecithin by albumin in human and rat plasma.''; PubMedEurope PMCScholia
Fielding CJ, Shore VG, Fielding PE.; ''Lecithin: cholesterol acyltransferase: effects of substrate composition upon enzyme activity.''; PubMedEurope PMCScholia
Quagliarini F, Wang Y, Kozlitina J, Grishin NV, Hyde R, Boerwinkle E, Valenzuela DM, Murphy AJ, Cohen JC, Hobbs HH.; ''Atypical angiopoietin-like protein that regulates ANGPTL3.''; PubMedEurope PMCScholia
Oeffner F, Fischer G, Happle R, König A, Betz RC, Bornholdt D, Neidel U, Boente Mdel C, Redler S, Romero-Gomez J, Salhi A, Vera-Casaño A, Weirich C, Grzeschik KH.; ''IFAP syndrome is caused by deficiency in MBTPS2, an intramembrane zinc metalloprotease essential for cholesterol homeostasis and ER stress response.''; PubMedEurope PMCScholia
Dubland JA, Francis GA.; ''Lysosomal acid lipase: at the crossroads of normal and atherogenic cholesterol metabolism.''; PubMedEurope PMCScholia
Vaughan AM, Oram JF.; ''ABCG1 redistributes cell cholesterol to domains removable by high density lipoprotein but not by lipid-depleted apolipoproteins.''; PubMedEurope PMCScholia
Eden ER, Patel DD, Sun XM, Burden JJ, Themis M, Edwards M, Lee P, Neuwirth C, Naoumova RP, Soutar AK.; ''Restoration of LDL receptor function in cells from patients with autosomal recessive hypercholesterolemia by retroviral expression of ARH1.''; PubMedEurope PMCScholia
Wang J, Hegele RA.; ''Homozygous missense mutation (G56R) in glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 (GPI-HBP1) in two siblings with fasting chylomicronemia (MIM 144650).''; PubMedEurope PMCScholia
Young SG, Davies BS, Voss CV, Gin P, Weinstein MM, Tontonoz P, Reue K, Bensadoun A, Fong LG, Beigneux AP.; ''GPIHBP1, an endothelial cell transporter for lipoprotein lipase.''; PubMedEurope PMCScholia
Bocharov AV, Vishnyakova TG, Baranova IN, Patterson AP, Eggerman TL.; ''Characterization of a 95 kDa high affinity human high density lipoprotein-binding protein.''; PubMedEurope PMCScholia
Silver DL, Tall AR.; ''The cellular biology of scavenger receptor class B type I.''; PubMedEurope PMCScholia
Hegele RA, Tu L, Connelly PW.; ''Human hepatic lipase mutations and polymorphisms.''; PubMedEurope PMCScholia
Takahashi K, Takeya M, Sakashita N.; ''Multifunctional roles of macrophages in the development and progression of atherosclerosis in humans and experimental animals.''; PubMedEurope PMCScholia
Poirier S, Mayer G, Benjannet S, Bergeron E, Marcinkiewicz J, Nassoury N, Mayer H, Nimpf J, Prat A, Seidah NG.; ''The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2.''; PubMedEurope PMCScholia
Gianturco SH, Ramprasad MP, Song R, Li R, Brown ML, Bradley WA.; ''Apolipoprotein B-48 or its apolipoprotein B-100 equivalent mediates the binding of triglyceride-rich lipoproteins to their unique human monocyte-macrophage receptor.''; PubMedEurope PMCScholia
Lee AH.; ''The role of CREB-H transcription factor in triglyceride metabolism.''; PubMedEurope PMCScholia
Fernández-Borja M, Bellido D, Vilella E, Olivecrona G, Vilaró S.; ''Lipoprotein lipase-mediated uptake of lipoprotein in human fibroblasts: evidence for an LDL receptor-independent internalization pathway.''; PubMedEurope PMCScholia
Sakai J, Hoshino A, Takahashi S, Miura Y, Ishii H, Suzuki H, Kawarabayasi Y, Yamamoto T.; ''Structure, chromosome location, and expression of the human very low density lipoprotein receptor gene.''; PubMedEurope PMCScholia
Qiu X, Mistry A, Ammirati MJ, Chrunyk BA, Clark RW, Cong Y, Culp JS, Danley DE, Freeman TB, Geoghegan KF, Griffor MC, Hawrylik SJ, Hayward CM, Hensley P, Hoth LR, Karam GA, Lira ME, Lloyd DB, McGrath KM, Stutzman-Engwall KJ, Subashi AK, Subashi TA, Thompson JF, Wang IK, Zhao H, Seddon AP.; ''Crystal structure of cholesteryl ester transfer protein reveals a long tunnel and four bound lipid molecules.''; PubMedEurope PMCScholia
Igarashi M, Osuga J, Uozaki H, Sekiya M, Nagashima S, Takahashi M, Takase S, Takanashi M, Li Y, Ohta K, Kumagai M, Nishi M, Hosokawa M, Fledelius C, Jacobsen P, Yagyu H, Fukayama M, Nagai R, Kadowaki T, Ohashi K, Ishibashi S.; ''The critical role of neutral cholesterol ester hydrolase 1 in cholesterol removal from human macrophages.''; PubMedEurope PMCScholia
Oram JF, Wolfbauer G, Vaughan AM, Tang C, Albers JJ.; ''Phospholipid transfer protein interacts with and stabilizes ATP-binding cassette transporter A1 and enhances cholesterol efflux from cells.''; PubMedEurope PMCScholia
Hegele RA, Little JA, Vezina C, Maguire GF, Tu L, Wolever TS, Jenkins DJ, Connelly PW.; ''Hepatic lipase deficiency. Clinical, biochemical, and molecular genetic characteristics.''; PubMedEurope PMCScholia
Wang X, Driscoll DM, Morton RE.; ''Molecular cloning and expression of lipid transfer inhibitor protein reveals its identity with apolipoprotein F.''; PubMedEurope PMCScholia
Du H, Sheriff S, Bezerra J, Leonova T, Grabowski GA.; ''Molecular and enzymatic analyses of lysosomal acid lipase in cholesteryl ester storage disease.''; PubMedEurope PMCScholia
Puglielli L, Konopka G, Pack-Chung E, Ingano LA, Berezovska O, Hyman BT, Chang TY, Tanzi RE, Kovacs DM.; ''Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid beta-peptide.''; PubMedEurope PMCScholia
Zhang DW, Lagace TA, Garuti R, Zhao Z, McDonald M, Horton JD, Cohen JC, Hobbs HH.; ''Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation.''; PubMedEurope PMCScholia
Berryman DE, Bensadoun A.; ''Heparan sulfate proteoglycans are primarily responsible for the maintenance of enzyme activity, binding, and degradation of lipoprotein lipase in Chinese hamster ovary cells.''; PubMedEurope PMCScholia
Vedhachalam C, Duong PT, Nickel M, Nguyen D, Dhanasekaran P, Saito H, Rothblat GH, Lund-Katz S, Phillips MC.; ''Mechanism of ATP-binding cassette transporter A1-mediated cellular lipid efflux to apolipoprotein A-I and formation of high density lipoprotein particles.''; PubMedEurope PMCScholia
Kozyraki R, Fyfe J, Kristiansen M, Gerdes C, Jacobsen C, Cui S, Christensen EI, Aminoff M, de la Chapelle A, Krahe R, Verroust PJ, Moestrup SK.; ''The intrinsic factor-vitamin B12 receptor, cubilin, is a high-affinity apolipoprotein A-I receptor facilitating endocytosis of high-density lipoprotein.''; PubMedEurope PMCScholia
Nakagawa M, Nishida T.; ''Effect of lysolecithin and albumin on lecithin-cholesterol acyltransferase activity in human plasma.''; PubMedEurope PMCScholia
Tiwari S, Siddiqi SA.; ''Intracellular trafficking and secretion of VLDL.''; PubMedEurope PMCScholia
Lobentanz EM, Krasznai K, Gruber A, Brunner C, Müller HJ, Sattler J, Kraft HG, Utermann G, Dieplinger H.; ''Intracellular metabolism of human apolipoprotein(a) in stably transfected Hep G2 cells.''; PubMedEurope PMCScholia
Becker A, Böttcher A, Lackner KJ, Fehringer P, Notka F, Aslanidis C, Schmitz G.; ''Purification, cloning, and expression of a human enzyme with acyl coenzyme A: cholesterol acyltransferase activity, which is identical to liver carboxylesterase.''; PubMedEurope PMCScholia
Chan CP, Mak TY, Chin KT, Ng IO, Jin DY.; ''N-linked glycosylation is required for optimal proteolytic activation of membrane-bound transcription factor CREB-H.''; PubMedEurope PMCScholia
Igarashi M, Osuga J, Isshiki M, Sekiya M, Okazaki H, Takase S, Takanashi M, Ohta K, Kumagai M, Nishi M, Fujita T, Nagai R, Kadowaki T, Ishibashi S.; ''Targeting of neutral cholesterol ester hydrolase to the endoplasmic reticulum via its N-terminal sequence.''; PubMedEurope PMCScholia
Navarese EP, Kolodziejczak M, Schulze V, Gurbel PA, Tantry U, Lin Y, Brockmeyer M, Kandzari DE, Kubica JM, D'Agostino RB, Kubica J, Volpe M, Agewall S, Kereiakes DJ, Kelm M.; ''Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis.''; PubMedEurope PMCScholia
Chau P, Nakamura Y, Fielding CJ, Fielding PE.; ''Mechanism of prebeta-HDL formation and activation.''; PubMedEurope PMCScholia
LDL (low density lipoproteins) are complexes of a single molecule of apoprotein B-100 (apoB-100) non-covalently associated with triacylglycerol, free cholesterol, cholesterol esters, and phospholipids. LDL complexes contain single molecules of apoB-100, but their content of lipids is variable (Chapman et al. 1988; Mateu et al. 1972; Tardieu et al. 1976). High levels of LDL in the blood are strongly correlated with increased risk of atherosclerosis, and recent studies have raised the possibility that this risk is further increased in individuals whose blood LDL population is enriched in high-density (low lipid content) LDL complexes (Rizzo and Berneis 2006). The LDL complex annotated here contains an average lipid composition.
LDL (low density lipoproteins) are complexes of a single molecule of apoprotein B-100 (apoB-100) non-covalently associated with triacylglycerol, free cholesterol, cholesterol esters, and phospholipids. LDL complexes contain single molecules of apoB-100, but their content of lipids is variable (Chapman et al. 1988; Mateu et al. 1972; Tardieu et al. 1976). High levels of LDL in the blood are strongly correlated with increased risk of atherosclerosis, and recent studies have raised the possibility that this risk is further increased in individuals whose blood LDL population is enriched in high-density (low lipid content) LDL complexes (Rizzo and Berneis 2006). The LDL complex annotated here contains an average lipid composition.
LDL (low density lipoproteins) are complexes of a single molecule of apoprotein B-100 (apoB-100) non-covalently associated with triacylglycerol, free cholesterol, cholesterol esters, and phospholipids. LDL complexes contain single molecules of apoB-100, but their content of lipids is variable (Chapman et al. 1988; Mateu et al. 1972; Tardieu et al. 1976). High levels of LDL in the blood are strongly correlated with increased risk of atherosclerosis, and recent studies have raised the possibility that this risk is further increased in individuals whose blood LDL population is enriched in high-density (low lipid content) LDL complexes (Rizzo and Berneis 2006). The LDL complex annotated here contains an average lipid composition.
LDL (low density lipoproteins) are complexes of a single molecule of apoprotein B-100 (apoB-100) non-covalently associated with triacylglycerol, free cholesterol, cholesterol esters, and phospholipids. LDL complexes contain single molecules of apoB-100, but their content of lipids is variable (Chapman et al. 1988; Mateu et al. 1972; Tardieu et al. 1976). High levels of LDL in the blood are strongly correlated with increased risk of atherosclerosis, and recent studies have raised the possibility that this risk is further increased in individuals whose blood LDL population is enriched in high-density (low lipid content) LDL complexes (Rizzo and Berneis 2006). The LDL complex annotated here contains an average lipid composition.
Dissociation of the LDL:LDLR complex in the early endosome frees the LDL particle to be transferred to lysosomes for degradation while the LDL receptor is returned to the plasma membrane (Goldstein et al. 1979).
Low density lipoprotein (LDL) particles associate with LDL receptors (LDLR) at the cell surface (Goldstein et al. 1979). This binding is mediated by the apoprotein B-100 component of the LDL particle, which binds LDLR with 1:1 stoichiometry (van Driel et al. 1989).
Low density lipoprotein (LDL) particles bound to their receptors (LDLR) in coated pits on the cell surface are taken up into clathrin-coated vesicles (Goldstein et al. 1979). In hepatocytes and lymphocytes, but not in fibroblasts, this process requires the presence of an additional protein, LDLRAP1 (ARH1). In human patients, LDLRAP1 deficiency is associated with hypercholesterolemia, emphasizing the central role of the liver in clearance of circulating LDL in vivo (Eden et al. 2002; Garuti et al. 2005; He et al. 2002; Michaely et al. 2004). In vitro, LDLRAP1 protein binds both to LDLR and to components of the clathrin coat, suggesting that it might play an essential bridging function during the movement of LDL:LDLR complexes into clathrin-coated vesicles. This role has not yet been demonstrated in vivo, however, nor is it clear what might substitute for such a bridging function in fibroblasts.
While the export pathway for nascent chylomicrons has not been directly characterized in human cells, the requirement for SAR1B protein for normal chylomicron export in vivo (Jones et al. 2003) indicates that nascent chylomicrons are exported from the endoplasmic reticulum via the Golgi apparatus in COPII vesicles.
Chylomicron micron remnants containing apolipoprotein E associate with the surfaces of cells in a process that probably involves several steps and that requires the presence (but not the catalytic activity) of heparan sulfate proteoglycan (HSPG)-associated hepatic lipase (HL). This process ultimately results in binding of the remnant to cell-surface LDL receptors (LDLR) (Ji et al. 1994). The molecular details of LDLR binding, and of the following steps of remnant endocytosis, are inferred from those of the coorresponding step of LDLR-mediated low-density lipoprotein (LDL) endocytosis. In the body, this process occurs in the liver.
Circulating nascent chylomicrons acquire copies of apolipoproteins C-II, C-III, and E from circulating spherical (mature) high-density lipoprotein particles, becoming mature chylomicrons (Havel et al. 1973; Bisgaier and Glickman 1983). Here, this interaction is annotated to involve the transfer of a single copy of each lipoprotein, but a mature chylomicron in fact contains approximately 25 copies of apolipoprotein E and 180 copies of C apolipoproteins (Bhattacharya and Redgrave 1981).
Triacylglycerol (TG)-depleted chylomicrons transfer A and C apoproteins to spherical (mature) HDL, generating chylomicron remnants (Havel and Kane 2001). This transfer is arbitrarily annotated here as involving one molecule of each apolipoprotein. The molecular difference that enables nascent chylomicrons to accept apolipoproteins from sperical HDL and TG-depleted chylomicrons to donate them is unclear.
The molecular details of this event are inferred from those of LDLR-mediated low-density lipoprotein (LDL) endocytosis into coated vesicles (Ji et al. 1994).
Newly synthesized apoB-48 that is not complexed with lipid is rapidly degraded (Dixon et al. 1991). The mechanism and site of this degradation (within the endoplasmic reticulum or in cytosolic proteasomes) is unclear.
In the body, this binding involved apoE synthesized by hepatocytes and concentrated in the space of Disse, an extracellular compartment adjacent to the hepatocytes to which blood-borne lipoprotein particles have free access (Ji et al. 1994).
The second phase of chylomicron assembly takes place in the lumen of the endoplasmic reticulum. ApoB-48 continues to bind triacylglycerol, as well as cholesterol, cholesterol esters, and molecules of apolipoproteins A-I, A-II, and A-IV. The reaction is annotated here to involve small numbers of these molecules, but the true numbers in vivo are much greater - a nascent chylomicron entering the lymphatic circulation contains >200,000 molecules of triacylglycerol (TG), ~35,000 of phospholipid, ~11,000 of cholesterol ester, ~8,000 of free cholesterol, ~60 copies of apolipoprotein A-I, ~15 copies of apolipoprotein A-IV, and copies of apolipoprotein A-II (Bhattacharya and Redgrave 1981; Havel and Kane 2001).
The presence of MTP:PDI (microsomal triacylglycerol transfer protein:protein disulfide isomerase) is required for lipid addition both in vitro and in vivo, but its molecular role at this stage of chylomicron formation is unclear and may be indirect (Gordon et al. 1995; Hussain et al. 2003).
Lipoprotein lipase dimers (LPL:LPL) are tethered to heparan sulfate proteoglycans (HSPG) at endothelial cell surfaces (Fernandez-Borja et al. 1996; Peterson et al. 1992). Both syndecan 1 (Rosenberg et al. 1997) and perlecan (Goldberg 1996) HSPG molecules are capable of tethering LPL. The LPL enzyme catalyzes the hydrolysis and release of triacylglycerols (TG) associated with circulating chylomicrons to leave a CM remnant (CR). This reaction is annotated here as causing the hydrolysis and release of 50 molecules of TG. In vivo, the number is much larger, and TG depletion probably occurs in the course of multiple encounters between a chylomicron and endothelial LPL. This reaction is strongly activated by chylomicron-associated apo C-II protein both in vivo and in vitro (Jackson et al. 1986). Chylomicron-associated apoC-II protein inhibits LPL activity in vitro (Brown and Baginsky 1972), and recent studies have indicated a positive regulatory role for apoA-5 protein, though its molecular mechanism of action remains unclear (Marcais et al. 2005; Merkel and Heeren 2005). CRs can then be taken up by liver parenchymal cells in two ways; 1) directly by the LDL receptor or 2) apoE/HSPG-directed uptake by LDL receptor-related proteins.
Phospholipid (PL) and triacylglycerol (TG) associate with the apo B-48 polypeptide as it is translated. This process is mediated by MTP (microsomal triacylglycerol transfer protein) in the form of a MTP:PDI (protein disulfide isomerase) heterodimer. MTP in vitro binds small amounts of PL and TG (annotated here as as one molecule of each) and efficiently transfers the bound lipid between membranes (Atzel and Wetterau 1994). In vivo, MTP:PDI directly interacts with apoB-48 polypeptide (Wu et al. 1996), and is thought to transfer lipid from the endoplasmic reticulum membrane to nascent apoB-48. While some of the molecular details of MTP function remain unclear, this function is clearly essential in vivo, as patients who lack MTP cannot produce chylomicrons (e.g., Wetterau et al. 1992; Narcisi et al. 1995).
The molecular details of this event are inferred from those of LDLR-mediated low-density lipoprotein (LDL) transport from coated vesicles to endosomes.
As an alternative to LDLR-mediated uptake and degradation, a LDL particle can bind a single molecule of LPA (apolipoprotein A), forming a Lp(a) lipoprotein particle. Although LPA is synthesized in liver cells, LPA - LDL binding appears to occur primarily extracellularly in vivo, on the hepatocyte surface or in the blood (Lobentanz et al. 1998). Lp(a) particles are relatively long-lived, with a half-life in human plasma of three to four days (Krempler et al. 1980), and the molecular mechanism of their clearance from the blood in vivo remains obscure. Lp(a) particles are of clinical interest because elevated levels of them are correlated with elevated risk of coronary heart disease (reviewed by Marcovina et al. 2003).
In an ATP-dependent reaction, ATP-binding cassette sub-family A member 1 (ABCA1, ATPA1) mediates the movement of intracellular cholesterol to the extracellular face of the plasma membrane. Cholesterol associated with cytosolic vesicles is a substrate for this reaction. Under physiologocal conditions, the active form of ABCA1 is predominantly a tetramer associated with apolipoprotein A-I (APOA1) (Denis et al. 2004; Vedhachalam et al., 2007). The number of lipid molecules transported per ATP consumed is not known.
ABCA1 associated with the plasma membrane binds extracellular apolipoprotein A-I (APOA1), forming a membrane-associated complex. The predominant form of ABCA1 is a heterotetramer (Denis et al. 2004), although studies in model systems in vitro are consistent with the hypothesis that the protein may also occur as a dimer (Trompier et al. 2006).
Extracellular apolipoprotein A-I interacts with phospholipid- and cholesterol-rich membrane patches formed through the action of ABCA1, binding these two lipids to form a discoidal (small nascent) HDL particle (HDL 3c - Kontush and Chapman 2006). The apoA-I molecules that accept lipids in this reaction appear to be different from the ones that activate ABCA1 at the plasma membrane (Hassan et al. 2007; Vedhachalam et al. 2007).
In an ATP-dependent reaction, ATPA1 mediates the movement of intracellular phospholipid to the extracellular face of the plasma membrane. Cholesterol associated with cytosolic vesicles is a substrate for this reaction. Under physiologocal conditions, the active form of ABCA1 is predominantly a tetramer associated with apolipoprotein A-I (APOA1) (Denis et al. 2004, Vedhachalam et al. 2007). The number of lipid molecules transported per ATP consumed is not known.
Serum albumin binds 2-lysophosphatidylcholine (lysolecithin) to form a complex. Two molecules of lipid bind strongly to a molecule of albumin; an additional five molecules bind more weakly (Nakagawa and Nishida 1973). The fate of the complex in vivo is unclear. In vitro 2-lysophosphatidylcholine can be esterified with fatty acid to generate phosphatidylcholine. Such a process could replenish the phosphatidylcholine consumed by cholesterol esterification in HDL particles, but the extent to which it occurs in vivo is unclear (Nakagawa and Nishida 1973; Switzer and Eder 1965).
LCAT activated by apoA-I catalyzes the reaction of cholesterol and phosphatidylcholine to yield cholesterol esterified with a long-chain fatty acid and 2-lysophosphatidylcholine. While this reaction was first studied in vitro using purified proteins in solution, it occurs in vivo on the surfaces of HDL particles where transiently-bound LCAT is activated by HDL-associated apoA-I protein and consumes HDL-associated cholesterol and phosphatidylcholine. The cholesterol ester reaction product is strongly associated with the HDL particle because of its increased hydrophobicity, while the 2-lysophosphatidylcholine product is released from the particle (Fielding et al. 1972 [2 references]; Adimoolam et al. 1998).
The six aminoterminal residues of pro-apolipoprotein A-1 are removed to generate the mature, lipid-binding form of the protein (APOA1). Studies of tissue culture systems suggest that BMP1 catalyzes this reaction (Chau et al. 2006, 2007). While BMP1 is annotated here as a monomer, its subunit structure is not known, and its 1:1 association with Zn2+ is inferred from its sequence similarity to known metallopeptidases. Tetrameric alpha2-macroglobulin (A2M) at concentrations found in plasma in inflammatory responses inhibits this reaction in vitro, suggesting a possible link between inflammation and perturbation of HDL function (Zhang et al. 2006, Chau et al. 2007).
ApoA-I bound to CUBN:AMN on the cell surface is endocytosed, moved to lysosomes, and degraded (Kozyraki et al. 1999). It is not known whether the CUBN:AMN complex is also degraded or recycled to the cell surface.
Extracellular apoA-I protein binds to the CUBN (cubilin) subunit of the CUBN:AMN complex associated with the plasma membrane. In the body, this complex is found on the apical surfaces of kidney glomerular cells, where it mediates binding and endocytosis of proteins in the glomerular filtrate, and on the apical surfaces of enterocytes, where it mediates uptake of several vitamins complexed with carrier proteins (notably vitamin B12 (cobalamin):intrinsic factor) (Kozyraki et al. 1999; Fyfe et al. 2004).
In an ATP-dependent reaction, ABCG1 mediates the movement of intracellular cholesterol to the extracellular face of the plasma membrane. In a tissue culture model system, the active form of ABCG1 is predominantly a tetramer (Vuaghan and Oram 2005). The number of lipid molecules transported per ATP consumed is not known.
Extracellular discoidal HDL particles interact with cholesterol-rich membrane patches formed through the action of ABCG1 (Vaughan and Oram 2005). In the body this reaction is a key step in the process of reverse cholesterol transport, by which excess cholesterol is recovered from cells such a macrophages and transported ultimately to the liver. At a molecular level, it is one of the steps in the transformation of discoidal (small nascent) HDL particles into spherical ones, distinct from the similar reaction in which cholesterol is transferred to lipid-free apoA-I protein (Oram and Vaughan 2006; Kontush and Chapman 2006).
Spherical (mature) HDL particles can acquire additional molecules of free cholesterol (CHOL) and phospholipid (PL) from cell membranes. In the body, this is an important step in the so-called reverse cholesterol transport process in which excess CHOLl, notably in foam cells in atherosclerotic plaques, is transferred to HDL particles and transported ultimately to the liver. While studies in vitro and in mutant mice indicate that PLTP (phospholipid transfer protein) plays a major role in this process, its molecular details remain unclear (Oram et al. 2003) and the reaction is annotated here as the addition of two molecules each of CHOL and PL to a spherical HDL to create an "enlarged" spherical HDL.
Spherical HDL particles can bind apoC-II, apoC-III and and apoE proteins. The sources of these proteins and their role or roles in HDL function under physiological conditions are not well understood, however (Kontush and Chapman 2006).
CETP (cholesterol ester transfer protein) complexed with triacylglycerol interacts with a spherical HDL (high density lipoprotein) particle, acquiring cholesterol ester molecules and donating triacylglycerol to the HDL (Swenson et al. 1988; Morton and Zilversmit 1983). This process is reversible but in the body proceeds in the direction annotated here. A model for the lipid exchange process has been proposed based on recent studies of the structure of CETP:lipid complexes (Qiu et al. 2007).
CETP (cholesterol ester transfer protein) complexed with cholesterol esters interacts with an LDL (low density lipoprotein) particle, acquiring triacylglycerol molecules and donating cholesterol ester to the LDL (Swenson et al. 1988; Morton and Zilversmit 1983). This process is reversible but in the body proceeds in the direction annotated here. A model for the lipid exchange process has been proposed based on recent studies of the structure of CETP:lipid complexes (Qiu et al. 2007).
Apolipoprotein F (APOF) can be associated with HDLs and LDLs. It can inhibit cholesteryl ester transfer protein (CETP) activity, thus inhibiting CETP-mediated transfer events specifically involving the LDL particle (Wang et al. 1999). The function of HDL-associated APOF, which represents >75% of the total plasma pool, is currently unknown. Although over-expression of mouse ApoF can accelerate plasma clearance of HDL (Lagor et al. 2009), physiological levels of ApoF do not affect HDL clearance (Lagor et al. 2012).
Apolipoprotein C-I (APOC1) is an Inhibitor of lipoproteins binding to their respective low density lipoprotein LDL receptor (LDLR), LDL receptor-related protein, and very low density lipoprotein receptor (VLDLR). It directly binds circulating fatty acids therby inhibiting their cellular uptake and is also the major plasma inhibitor of CETP (Westerterp et al. 2007).
Torcetrapib associates with a molecule of CETP and a spherical HDL particle to form a stable complex, thus trapping CETP and inhibiting CETP-mediated lipid transfer between HDL and LDL (Clark et al. 2006).
An extracellular spherical HDL particle binds to the plasma membrance-associated SR-BI receptor with high affinity (Murao et al. 1997). In the body SR-BI receptors are abundant on the surfaces of steroidogenic cells in the adrenal glands and gonads, and on hepatocytes. SR-BI thus appears to play a central role in cholesterol uptake for steroid hormone synthesis and for bile acid synthesis and cholesterol excretion (Rigotti et al. 2003; Silver and Tall 2001).
Spherical HDL particles bound to the cell-surface SR-BI receptor are disassembled, with the release of pre-beta HDL (essentially apoA-I lipoprotein with a few molecules of bound lipid) and the cellular uptake of the bulk of the HDL-associated cholesterol, cholesterol esters, phospholipids, and triacylglycerols. The specificity and efficiency of this process has been demonstrated through a variety of studies in tissue culture model systems (Rigotti et al. 2003; Silver and Tall 2001). The process is annotated here as a concerted event occuring at the cell surface but its molecular details remain incompletely defined and it is possible that the HDL particle is internalized while undergoing disassembly.
Pre-beta HDL (lipid-poor apoA-I) interacts with phospholipid- and cholesterol-rich membrane patches formed through the action of ABCA1, binding these two lipids to form a discoidal (small nascent) HDL particle (HDL 3c - Kontush and Chapman 2006).
Palmitoylation of ATP-binding cassette sub-family A member 1 (ABCA1) at Cys 3, 23, 1110 and 1111 is essential for its proper trafficking from the ER membrane to the plasma membrane where it is essential for the transport of lipids. The probable palmitoyltransferase ZDHHC8 mediates the palmitoylation of ABCA1 (Singaraja et al. 2009).
ATP-binding cassette sub-family A member 1 (ABCA1) is a key mediator of cholesterol and phospholipid efflux to apolipoprotein particles. This efflux activity is regulated by protein kinase A (PKA) site-specific phosphorylation of ABCA1 at Ser-1042 and Ser-2054, located in the nucleotide binding domains of ABCA1 (See et al. 2002).
Palmitoylation of ATP-binding cassette sub-family A member 1 (ABCA1) at Cys 3, 23, 1110 and 1111 is essential for its proper trafficking from the ER membrane to the plasma membrane where it is essential for the transport of lipids (Singaraja et al. 2009).
Fatty acids (FAs) are used as energy substrates and are stored as triglycerides. Triacylglycerol (TAG) has to be cleaved by lipases to be able to move in and out of cells for usage. Hepatic triacylglycerol lipase (LIPC) is one of several enzymes that catalyses the hydrolysis of TAGs to free fatty acids (FAs) and diacylglycerol (DAG) (Hegele et al. 1993, Santamarina-Fojo et al. 2004). Defects in LIPC can cause hepatic lipase deficiency (HL deficiency; MIM:614025), a disorder characterised by premature atherosclerosis and abnormal circulating lipoproteins (Hegele et al. 1992, 1993).
Cyclic AMP-responsive element-binding protein 3-like protein 3 (CREB3L3) is a transcription factor that is highly and selectively expressed in liver and small intestine. This protein is produced as an ER-localized type II transmembrane glycoprotein that is converted into the mature nuclear form (the N-terminal portion) by sequence specific proteases, membrane-bound transcription factor site-1 proteases 1 and 2 (MBTPS1 and 2) (Marschner et al. 2011, Oeffner et al. 2009). CREB3L3 is a downstream target gene of hepatocyte nuclear factor 4a (HNF-4a), which plays a critical role in hepatocyte differentiation and liver function. Ablation of HNF-4a abolished CREB-H mRNA expression in the liver, but not in the small intestine, suggesting an essential role of HNF-4a in hepatic CREB-H expression.
Crebh(1-?) enters the nucleoplasm and induces the expression of APOA4, APOA5, APOC2, CIDEC and FGF21 (Lee et al. 2011). APOA4, APOA5 and APOC2 are known to augment lipoprotein lipase (LPL) activity. LPL is bound to the vascular endothelium, and hydrolyzes chylomicron and VLDL- associated TG to facilitate the transport of hydrolyzed fatty acids to peripheral cells. Patients with genetic defects in AOPC2, APOA5 or LPL display high circulating TG levels due to impaired TG clearance. Identification of APOA4, APOA5 and APOC2 as CREB-H target genes suggests that CREB-H might be involved in TG catabolism. CREB-H also strongly induces FGF21, a liver expressed hormone that has antidiabetic and TG- lowering effects, and CIDEC which encodes a lipid droplet-associated protein (Lee 2012).
LPL enzyme is catalytically active as a dimer composed of two glycosylated subunits of LPL connected in a head-to-tail arrangement by non-covalent interactions. Dimeric LPL is cleaved by several proprotein convertases. FURIN and proprotein convertase subtilisin/kexin type 6 (PCSK6 aka PACE4) can cleave LPL dimer, inactivating it, resulting in subsequent increase in plasma TG concentrations (Siezen et al. 1994, Bassi et al. 2000, Jin et al. 2005). Endogenous modulators of LPL are the angiopoietin-like proteins ANGPTL3 and ANGPTL4, which can bind transiently to LPL dimer, resulting in conversion of the enzyme from a catalytically active dimer to inactive, but still folded, monomers (Liu et al. 2010, Sukonina et al. 2006). ANGPTL4 regulates plasma triglyceride concentration via the inhibition of LPL (Dijk & Kersten 2014). GWAS studies (Dewey et al. 2016, MIG and CARDIoGRAM Consortium 2016) show a strong correlation between inactivating ANGPTL4 mutants and lower levels of triglycerides and lower risk of coronary artery disease than non-carriers. Therapeutic modulation of ANGPTL4 could be a new strategy against dyslipidemia (Kersten 2016).
The N-terminal fragment of CREB3L3 is released to the cytosol and translocates to the nucleus (Chan et al. 2010, Chin et al. 2005) to induce the transcriptional activation of different genes such as Apoa4, Apoa5, and Apoc2 apolipoproteins which exhibit stimulatory effects on lipoprotein lipase (LPL). Consistent with the essential role of LPL in TG clearance, CREB3L3-deficient mice showed hypertriglyceridemia, associated with defective production of these apolipoproteins and decreased LPL activity.
LPL enzyme is catalytically active as a dimer composed of two glycosylated subunits of LPL connected in a head-to-tail arrangement by non-covalent interactions. Dimeric LPL is cleaved by several proprotein convertases. Proprotein convertase subtilisin/kexin type 5 (PCSK5) can cleave LPL dimer, inactivating it, resulting in subsequent increase in plasma TG concentrations (Paule et al. 2012). ANGPTL4 binds transiently to LPL dimer, the interaction resulting in conversion of the enzyme from a catalytically active dimer to inactive, but still folded, monomers (Sukonina et al. 2006).
The PCSK9:LDLR:Clathrin-coated vesicle is internalized to endosomes and, after that, to lysosomes where PCSK9 and LDLR are degraded (Wang et al. 2012).
PCSK9 (Proprotein convertase subtilisin/kexin type 9) binds to LDLR (Low-density lipoprotein receptor) on the cell surface. The binding site of PCSK9 has been localized to the epidermal growth factor-like repeat A (EGF-A) domain of the LDLR (Zhang et al. 2007). The complex PCSK9:LDLR is internalized via clathrin-mediated endocytosis and then routed to lysosomes via a mechanism that does not require ubiquitination and is distinct from the autophagy and proteosomal degradation pathways. In lysosomes, the affinity of the interaction between PCSK9 and LDLR dramatically increases. This promotes the final degradation of PCSK9 and LDLR without recycling. Monoclonal antibodies targeting PCSK9 have been shown to markedly reduce LDL cholesterol levels and are a novel treatment strategy for adults with hypercholesterolemia (Navarese et al. 2015).
LDLR that engage PCSK9 at the cell membrane are internalized via the canonical clathrin-dependent endocytic machinery (Wang et al. 2012). This complex is routed to lysosomes via a pathway that does not require ubiquitination of the cytoplasmic tail of the receptor and does not involve the proteasomal or autophagy pathways. The clathrin is required for the internalization of the LDLR-PCSK9 complex that forms on the cell surface.
LDLR that engage PCSK9 at the cell membrane are internalized via the canonical clathrin-dependent endocytic machinery (Wang et al. 2012). This complex is routed to lysosomes via a pathway that does not require ubiquitination of the cytoplasmic tail of the receptor and does not involve the proteasomal or autophagy pathways. The clathrin is required for the internalization of the LDLR-PCSK9 complex that forms on the cell surface.
LPL enzyme is catalytically active as a dimer composed of two glycosylated subunits of LPL connected in a head-to-tail arrangement by non-covalent interactions. It is synthesised in adipocytes and exported to the luminal side of the capillary endothelium where it binds heparan sulfate proteoglycan (HSPG), serving as an membrane anchor for the LPL dimer (Lookene et al. 1997, Berryman & Bensadoun 1995).
Hepatic triacylglycerol lipase (LIPC, and lipoprotein lipase, LPL) are dimeric lipases (Hill et al. 1997) that hydrolyse triglycerides from circulating lipoproteins thereby playing important roles in lipoprotein remodeling and uptake. LIPC dimer (as well as LPL dimer) binds to an ER membrane protein known as lipase maturation factor 1 (LMF1) which can mediate secretion and enzymatic maturation of these lipases. Human LMF1 contain five TM segments that divide the protein into six separate domains with cytoplasmic and ER lumenal orientation thereby transporting LIPC dimer from ER lumen to the cytosol. The mechanism of LIPC dimer translocation from cytosol to secretion is unknown (Doolittle et al. 2009, Babilonia-Rosa & Neher 2014). Another family member, LMF2, may function as LMF1 based on similarity. Defects in LMF1 can cause combined lipase deficiency (CLD; MIM:246650), characterised by hypertriglyceridemia caused by ER retention of both LIPC dimer and LPL dimer (Peterfy et al. 2007).
Hepatic triacylglycerol lipase (LIPC, and lipoprotein lipase, LPL) are dimeric lipases (Hill et al. 1997) that hydrolyse triglycerides from circulating lipoproteins thereby playing important roles in lipoprotein remodeling and uptake. LIPC dimer (as well as LPL dimer) binds to an ER membrane protein known as lipase maturation factor 1 (LMF1) which can mediate secretion and enzymatic maturation of these lipases (Doolittle et al. 2009, Babilonia-Rosa & Neher 2014). Another family member, LMF2, may function as LMF1 based on similarity. Defects in LMF1 can cause combined lipase deficiency (CLD; MIM:246650), characterised by hypertriglyceridemia caused by ER retention of both LIPC and LPL (Peterfy et al. 2007).
NCEH1 (neutral cholesterol ester hydrolase) hydrolyzes cholesterol esters to form cholesterol (CHOL) and free fatty acids (LCFA). In both humans (Igarashi et al. 2010a) and mice (Igarashi et al. 2010b, Okazaki et al. 2008, Sakai et al. 2014 ) NCEH1 associated with the endoplasmic reticulum membrane appears to play a major role in cholesterol ester hydrolysis in macrophages. Free CHOL is transported via transport vesicles and can be used for cellular functions or removed from the cell by ABCA1 to create new HDL particles.
Apolipoprotein B receptor (APOBR dimer) is a dimeric lipid binding receptor on the surface of macrophages. It can bind to and internalise dietary triglyceride-rich lipoproteins (TRLs) and hypertriglyceridemic very low density lipoproteins (HTG-VLDLs), both represented here by VLDL (Gianturco et al. 1998, Brown et al. 2000). APOBR dimer binds to APO-B48 in TRLs or the APO-B48 equivalent domain of APO-B100 in HTG-VLDLs (Bradley et al. 1999). Macrophages can play multifunctional roles in the pathogenesis and progression of atherosclerosis, in which they are important for intracellular lipid accumulation and foam cell formation. Lipid-filled foam cells are seen in atherosclerotic lesions (Brown et al. 2000, Takahashi et al. 2002). PPAR alpha and gamma activators and the blood cholesterol-lowering statin pitavastatin suppress the APOBR pathway in vivo, diminishing APOBR-mediated macrophage lipid accumulation and suggesting an antiatherogenic effect for these suppressors (Haraguchi et al. 2003, Kawakami et al. 2005).
Very low-density lipoproteins (VLDLs) are produced in the liver to transport endogenous triglycerides, phospholipids, cholesterol, and cholesteryl esters in the hydrophilic environment of the bloodstream. They comprise triglycerides (50-60%), cholesterol (10-12%), cholesterol esters (4-6%), phospholipids (18-20%), and apolipoprotein B (8-12%). Of the protein content, two other apolipoproteins are constituents; apolipoprotein C-I (APOC around 20%) (Westerterp et al. 2007) and apolipoprotein C4 (APOC4, minor amount) (Kotite et al. 2003). After release from the liver, circulating VLDL particles can bind very low-density lipoprotein receptors (VLDLR) (Sakai et al. 1994) on extra-hepatic target cells and undergo endocytosis (Go & Mani 2012). VLDL uptake by VLDLR represents a minor contribution towards VLDL metabolism. The majority of VLDL is catalysed by lipoprotein lipase (LPL) which hydrolyses TAGs from VLDL, converting it to intermediate-density lipoprotein (IDL). IDL can be further hydrolysed by hepatic lipase to cholesterol-rich low-density lipoprotein (LDL).
VLDLR consists of five functional domains that resemble the LDL receptor. It is highly expressed in tissues that actively metabolise fatty acids as a source of energy. Binding of VLDLs to VLDLR appears to be inhibited by apolipoprotein C-I (APOC1), therby slowing the clearance of triglyceride-rich lipoproteins from the circulation (Westerterp et al. 2007). The APOE/C1/C4/C2 gene cluster is closely associated with plasma lipid levels, atherosclerotic plaque formation, and thereby implicated in the development of coronary artery disease and Alzheimer’s disease (Xu et al. 2015).
The E3 ubiquitin-protein ligase (MYLIP, aka IDOL) mediates the ubiquitination and subsequent proteasomal degradation of myosin regulatory light chain (MRLC), LDLR, VLDLR and LRP8. It acts as a sterol-dependent inhibitor of cellular cholesterol uptake by mediating degradation of LDLR (Hong et al. 2010). Despite some similarities, the MYLIP and PCSK9 ubiquitination pathways for controlling (V)LDLR abundance appear to be independent of each other. MYLIP is a transcriptional target of liver X receptors (NR1H2 and NR1H3), which can increase MYLIP expression and hence decerease (V)LDLR levels (Zelcer et al. 2009, Hong et al. 2010, Sorrentino & Zelcer 2010, Zhang et al. 2012).
Circulating proprotein convertase subtilisin/kexin type 9 (PCSK9) is an important regulator of plasma cholesterol homeostasis by binding to low-density lipid receptor family members and promoting their degradation in lysosomes (Poirier et al. 2008). In mice, it was observed that circulating PCSK9 can regulate VLDLR protein levels in adipose tissue and thereby, fat accumulation. The absence of PCSK9 led to an increase in lipid uptake resulting in adipocyte hypertrophy which was LDLR-independent (Roubtsova et al. 2011). Whether increased fat deposition also occurs in humans lacking functional PCSK9 remains to be elucidated.
Once proprotein convertase subtilisin/kexin type 9 (PCSK9) binds to very low-density lipoprotein receptor (VLDLR), the resultant complex is internalised via the canonical clathrin-dependent endocytic machinery. This degradation route that does not require ubiquitination of the cytoplasmic tail of the receptor and does not involve proteasomal or autophagy pathways. The PCSK9:VLDLR:Clathrin-coated vesicle complex translocates from the plasma membrane, via endosomes to the lysosomal membrane where the receptor is degraded (Zhang et al. 2007, Poirier et al. 2008).
Once proprotein convertase subtilisin/kexin type 9 (PCSK9) binds to very low-density lipoprotein receptor (VLDLR), the resultant complex is internalised via the canonical clathrin-dependent endocytic machinery. This degradation route that does not require ubiquitination of the cytoplasmic tail of the receptor and does not involve proteasomal or autophagy pahtways (Zhang et al. 2007, Poirier et al. 2008).
Angiopoietin-like proteins (ANGPTLs) play major roles in the trafficking and metabolism of lipids. Angiopoietin-like protein 8 (ANGPTL8, aka betatrophin, lipasin) can regulate ANGPTL3 by binding to and promoting cleavage of it, thereby further activating ANGPTL3 (a protein that plays a critical role in the regulation of triglyceride and cholesterol plasma levels, via reversible inhibition of lipoprotein lipase activity) (Ren et al. 2012, Quagliarini et al. 2012, Li & Teng 2014). The exact mechanism of action of ANGPTL8 on ANGPTL3 is poorly understood.
Lipoprotein lipase (LPL) is mainly produced by adipocytes and myocytes but is also involved in hydrolysing triglyceride-rich lipoproteins in the lumen of capillaries of heart, adipose tissue, and skeletal muscle. Heparan sulfate proteoglycan (HSPG) serves as an membrane anchor for LPL dimer but for LPL to reach its site of action in capillaries, it binds to glycosylphosphatidylinositol-anchored high density lipoprotein-binding protein 1 (GPIHBP1), an endothelial cell membrane-bound protein. Once bound, GPIHBP1 transports LPL from within interstitial spaces, across endothelial cells to the capillary lumen (Gin et al. 2007, Young et al. 2011, Adeyo et al. 2012). Defects in GPIHBP1 can cause mislocalisation of LPL leading to severe hypertriglyceridaemia and hyperlipoproteinemia type ID (MIM:615947) (Adeyo et al. 2012, Wang & Hegele 2007, Beigneux et al. 2009, Beigneux et al. 2015).
Vigilin (HDL-binding protein, HDLBP) predominantly resides on most human cell membranes and binds high-density lipoproteins (HDLs). Although its role remains unclear, Vigilin may mediate removal of excess intracellular cholesterol (Bocharov et al. 2001).
Lysosomal acid lipase/cholesteryl ester hydrolase (LIPA, aka lysosomal acid lipase, LAL) is structurally related to previously described enteric acid lipases and catalyses the deacylation of triacylglyceryl and cholesteryl ester core lipids of endocytosed low density lipoproteins (LDLs) (Anderson & Sando 1991, Ameis et al. 1994). LIPA is catalytically active in monomeric form. Defects in LIPA can cause Wolman disease (WOD; MIM:278000), a lysosomal lipid storage disorder where cholesteryl esters and triglycerides accumulate in most tissues of the body. WOD occurs in infancy and is nearly always fatal before the age of 1 (Anderson et al. 1994, Du et al. 1998).
Atherosclerosis is characterised by the accumulation of excess cholesterol in the artery wall. In later stages of atherosclerosis, both free cholesterol and cholesteryl ester droplets accumulate within the lysosome. As the cholesterol level increases, it inhibits the proton pumping ability of the vATPases, the pH inside the lysosome increases and renders LIPA catalytically inactive, contributing further to the progression of atherosclerosis (Dubland & Francis 2015).
The assembly of very low-density lipoprotein (VLDL) occurs in two steps (Olofsson et al. 2000). In the second step, pre-VLDL in the smooth ER lumen binds the major lipids that form bona fide VLDL; triacylglycerols (TAG) (50%), phospholipids (PL) (20%), cholesterol (CHOL) (10%) and cholesteryl esters (CHEST) (5%).
For the formation of bona fide VLDL, pre-VLDL must translocate from the rough ER membrane to smooth ER lumen where it acquires the major lipids (Olofsson et al. 2000).
Newly formed very low-density lipoprotein (VLDL) released from the liver can acquire lipoproteins in the circulation. Apolipoprotein C-I (APOC1) is a 6.6 kDa apolipoprotein that is synthesised mainly in the liver but also in other tissues. It is a constituent of triglyceride-rich lipoproteins (around 10% of the protein of VLDLs and 2% of HDLs) that slow the circulatory clearance of triglyceride-rich lipoproteins by a variety of mechanisms. As well as binding and inhibiting triglyceride-rich lipoprotein uptake by the very low-density lipoprotein receptor (VLDLR), it can also binds free fatty acids (FAs) in the circulation, reducing their uptake by cells (Shachter 2001, Hansen et al. 2011). A minor constituent of VLDL is apolipoprotein IV (APO4) (Kotite et al. 2003).
The assembly of very low-density lipoprotein (VLDL) occurs in two steps (Olofsson et al. 2000). In the first step, apolipoprotein B-100 (APOB(28-4563), APOB-100) is co- and post-translationally lipidated by MTP (microsomal triacylglycerol transfer protein) in the form of a MTP:PDI (protein disulfide isomerase) heterodimer (Gordon et al. 1995), forming a pre-VLDL. This occurs in the rough endoplasmic reticulum (RER) lumen. The pre-VLDL is loosely associated with the RER membrane. MTP in vitro binds small amounts of PL and TAG (annotated here as one molecule of each) and efficiently transfers the bound lipid between membranes (Atzel & Wetterau 1994). In vivo, MTP:PDI directly interacts with APOB-100 polypeptide (Wu et al. 1996), and is thought to transfer lipid from the endoplasmic reticulum membrane to nascent APOB-100. In humans, APOB-100 is expressed in the liver and forms VLDL whereas APOB-48 is expressed in the intestine and forms chylomicrons.
Once low-density lipoprotein (LDL) is freed from the LDLR to the endosomal lumen, it translocates to the lysosomal lumen for degradation via a receptor-mediated endocytotic mechanism (Goldstein et al. 1979).
In macrophages, the hydrolysis of cholesteryl esters (CHESTs) is the rate-limiting step in the removal of free cholesterol (CHOL) from these cells. CHOL is transported via transport vesicles and can be used for cellular functions or removed from the cell by ABCA1 to create new HDL particles. Accumulation of CHESTs in macrophage foam cells is key to atherosclerotic plaque formation (Dubland & Francis 2015). Exit from lysosomes of CHOL derived from the hydrolysis of CHESTs in low-density lipoproteins (LDLs) requires the concerted effort of two proteins, membrane-bound Niemann-Pick C1 (NPC1) and soluble NPC2. In the first step, NPC2 binds unesterified CHOL that has been released from LDLs in the lumen of lysosomes (Liou et al. 2006).
In macrophages, the hydrolysis of cholesteryl esters (CHESTs) is the rate-limiting step in the removal of free cholesterol (CHOL) from these cells. CHOL is transported via transport vesicles and can be used for cellular functions or removed from the cell by ABCA1 to create new HDL particles. Accumulation of CHESTs in macrophage foam cells is key to atherosclerotic plaque formation (Dubland & Francis 2015).
Exit from lysosomes of CHOL derived from the hydrolysis of CHESTs in low-density lipoproteins (LDLs) requires the concerted effort of two proteins, membrane-bound Niemann-Pick C1 (NPC1) and soluble NPC2. In the second step, NPC2 transfers CHOL to the CHOL-binding pocket of the N-terminal domain of NPC1 (Infante et al. 2008). During the transfer of CHOL from NPC2 to NPC1, the orientation of CHOL is reversed, allowing insertion of its isooctyl side chain into the outer lysosomal membrane (Kwon et al. 2009).
In macrophages, the hydrolysis of cholesteryl esters (CHESTs) is the rate-limiting step in the removal of free cholesterol (CHOL) from these cells. CHOL is transported via transport vesicles and can be used for cellular functions or removed from the cell by ABCA1 to create new HDL particles. Accumulation of CHESTs in macrophage foam cells is key to atherosclerotic plaque formation (Dubland & Francis 2015).
CHOL is positioned on the outer membrane of lysosomes and translocates to the ER membrane where it can be re-esterified for storage. The mechanism of translocation is currently unknown (Infante et al. 2008).
Excess cellular cholesterol (CHOL) is esterified and stored as cholesteryl ester (CHEST). The conversion is catalysed by the ER membrane-residing sterol O-acyltransferases 1 and 2 (SOAT1 and SOAT 2, aka acyl-coenzyme A:cholesterol acyltransferase 1 and 2, ACAT1 and 2) (Chang et al. 1993, Oelkers et al. 1998, Lin et al. 1999). CHESTs are usually present at low levels in most cells but chronic accumulation of CHEST in macrophages causes these cells to appear foamy and is a characteristic of early stage atherosclerosis (Becker et al. 1994). The SOAT enzymes are being investigated as potential drug targets for atherosclerosis and for Alzheimer's disease (Chang et al. 2009). Alzheimer's disease is a prevalent neurodegenerative disease, characterised by a large extracellular accumulation of amyloid plaques, composed mainly of beta-amyloid peptide aggregates. Increases in free cholesterol in the membrane, which can be caused by inhibiting ACAT1, can lead to the decrease of amyloid precursor protein processing. Pharmacological inhibitors of ACAT1 are potential treatment routes for Alzheimer's disease (Puglielli et al. 2001, Chang et al. 2009, Zhu et al. 2015).
Cholesterol that has been esterified by sterol O-acyltransferases at the ER membrane to cholesteryl esters (CHESTs) are stored in lipid particles present in the cytosol (Daugherty et al. 2008).
The human lipolysis-stimulated lipoprotein receptor (LSR, LISCH) probably plays a role in the clearance of triglyceride-rich lipoproteins from blood, allowing their subsequent uptake into cells. Its affinity is highest for those lipoproteins most susceptible to lipolysis such as chylomicrons, LDL and VLDL. Human LSR function is inferred from mouse Lsr expression, functional and gene silencing studies (Yen et al. 1999, Mesli et al. 2004, Yen et al. 2008). Lsr inactivation in mice during embryogenesis resulted in death and indicated expression of Lsr was critical for liver and embryonic development (Mesli et al. 2004). This reaction shows LSR binding LDL.
The human lipolysis-stimulated lipoprotein receptor (LSR, LISCH) probably plays a role in the clearance of triglyceride-rich lipoproteins from blood, allowing their subsequent uptake into cells. Its affinity is highest for those lipoproteins most susceptible to lipolysis such as chylomicrons, LDL and VLDL. Human LSR function is inferred from mouse Lsr expression, functional and gene silencing studies (Yen et al. 1999, Mesli et al. 2004, Yen et al. 2008). Lsr inactivation in mice during embryogenesis resulted in death and indicated expression of Lsr was critical for liver and embryonic development (Mesli et al. 2004). This reaction shows LSR binding VLDL.
In macrophage foam cells, the hydrolysis of cholesteryl esters (CHESTs) is the rate-limiting step in the removal of free cholesterol (CHOL) from these cells. CHOL is transported via transport vesicles and can be used for cellular functions or removed from the cell by ABCA1 to create new HDL particles. Accumulation of CHESTs in macrophage foam cells is key to atherosclerotic plaque formation and occurs as a result of an imbalance between CHOL influx and efflux pathways. The main hydrolase that hydrolyses CE in macrophages is neutral cholesterol ester hydrolase 1 (NCEH1). Carboxylesterases (CESs), usually involved in the hydrolysis of drugs, can also hydrolyse CHESTs with CES1 responsible for >70% of the total CES hydrolytic activity in macrophages, thus playing an important antiatherogenic role. CES1 knockdown studies reveal a compensatory increase in the expression of CES3, expressed at <30% of the level of CES1 in human macrophages, which restores intracellular CHEST hydrolytic activity and CHOL efflux (Zhao et al. 2012). Human CES3 isoproteins are predicted to be either secreted or retained in the cytosol (Holmes et al. 2010) but the exact location is currently unknown.
Dimeric lipase G (LIPG) catalyzes the hydrolysis of triglycerides (TAG) associated with high-density lipoprotein particles to diglycerides (DAG) and long-chain fatty acids (LCFA) (Griffon et al. 2009).
Try the New WikiPathways
View approved pathways at the new wikipathways.org.Quality Tags
Ontology Terms
Bibliography
History
External references
DataNodes
HDL:torcetrapib
complexremnant:apoE
complexremnant:apoE
complexremnant:apoE:LDLR
complexremnant:apoE:LDLR
complexremnant:apoE:LDLR
complexHDL:triacylglycerol
complexAnnotated Interactions
HDL:torcetrapib
complexThe presence of MTP:PDI (microsomal triacylglycerol transfer protein:protein disulfide isomerase) is required for lipid addition both in vitro and in vivo, but its molecular role at this stage of chylomicron formation is unclear and may be indirect (Gordon et al. 1995; Hussain et al. 2003).
Apolipoprotein F (APOF) can be associated with HDLs and LDLs. It can inhibit cholesteryl ester transfer protein (CETP) activity, thus inhibiting CETP-mediated transfer events specifically involving the LDL particle (Wang et al. 1999). The function of HDL-associated APOF, which represents >75% of the total plasma pool, is currently unknown. Although over-expression of mouse ApoF can accelerate plasma clearance of HDL (Lagor et al. 2009), physiological levels of ApoF do not affect HDL clearance (Lagor et al. 2012).
Apolipoprotein C-I (APOC1) is an Inhibitor of lipoproteins binding to their respective low density lipoprotein LDL receptor (LDLR), LDL receptor-related protein, and very low density lipoprotein receptor (VLDLR). It directly binds circulating fatty acids therby inhibiting their cellular uptake and is also the major plasma inhibitor of CETP (Westerterp et al. 2007).
VLDLR consists of five functional domains that resemble the LDL receptor. It is highly expressed in tissues that actively metabolise fatty acids as a source of energy. Binding of VLDLs to VLDLR appears to be inhibited by apolipoprotein C-I (APOC1), therby slowing the clearance of triglyceride-rich lipoproteins from the circulation (Westerterp et al. 2007). The APOE/C1/C4/C2 gene cluster is closely associated with plasma lipid levels, atherosclerotic plaque formation, and thereby implicated in the development of coronary artery disease and Alzheimer’s disease (Xu et al. 2015).
Atherosclerosis is characterised by the accumulation of excess cholesterol in the artery wall. In later stages of atherosclerosis, both free cholesterol and cholesteryl ester droplets accumulate within the lysosome. As the cholesterol level increases, it inhibits the proton pumping ability of the vATPases, the pH inside the lysosome increases and renders LIPA catalytically inactive, contributing further to the progression of atherosclerosis (Dubland & Francis 2015).
remnant:apoE
complexremnant:apoE
complexremnant:apoE
complexremnant:apoE:LDLR
complexremnant:apoE:LDLR
complexremnant:apoE:LDLR
complexremnant:apoE:LDLR
complexremnant:apoE:LDLR
complexremnant:apoE:LDLR
complexHDL:triacylglycerol
complex